Avalon Pharmaceuticals Inc - Current report filing (8-K)

 

 

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):		October 12, 2007

AVALON PHARMACEUTICALS, INC.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	001-32629	52-2209310
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
20358 Seneca Meadows Parkway, Germantown, Maryland		20876
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code:		301-556-9900

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Top of the Form

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On October 12, 2007, Dr. Alan G. Walton, a director of Avalon Pharmaceuticals, Inc. ("Avalon"), announced that he plans to resign from his position with Avalon effective November 1, 2007. The text of Avalon's press release announcing the resignation of Dr. Walton is set forth in Exhibit 99.1 to this report and is incorporated by reference into this item.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number ..... Description
99.1 ..........................Press Release dated October 12, 2007.

---

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		AVALON PHARMACEUTICALS, INC.
October 15, 2007		By:		Thomas G. David, Esq.
				Name: Thomas G. David, Esq.
				Title: General Counsel

---

Top of the Form

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated October 12, 2007.